Peapod Lane Capital LLC Boosts Stake in OraSure Technologies, Inc. $OSUR

Peapod Lane Capital LLC raised its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) by 16.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 666,607 shares of the medical instruments supplier’s stock after purchasing an additional 95,497 shares during the quarter. OraSure Technologies accounts for 2.0% of Peapod Lane Capital LLC’s holdings, making the stock its 18th largest holding. Peapod Lane Capital LLC owned 0.89% of OraSure Technologies worth $2,000,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Gagnon Securities LLC grew its stake in shares of OraSure Technologies by 49.4% in the second quarter. Gagnon Securities LLC now owns 1,604,142 shares of the medical instruments supplier’s stock valued at $4,812,000 after buying an additional 530,371 shares in the last quarter. Gagnon Advisors LLC grew its stake in shares of OraSure Technologies by 51.4% in the second quarter. Gagnon Advisors LLC now owns 1,207,440 shares of the medical instruments supplier’s stock valued at $3,622,000 after buying an additional 410,163 shares in the last quarter. Significant Wealth Partners LLC grew its stake in shares of OraSure Technologies by 36.1% in the second quarter. Significant Wealth Partners LLC now owns 36,837 shares of the medical instruments supplier’s stock valued at $111,000 after buying an additional 9,770 shares in the last quarter. Bfsg LLC grew its stake in shares of OraSure Technologies by 8.3% in the second quarter. Bfsg LLC now owns 45,680 shares of the medical instruments supplier’s stock valued at $137,000 after buying an additional 3,490 shares in the last quarter. Finally, Farther Finance Advisors LLC acquired a new stake in shares of OraSure Technologies in the second quarter valued at $26,000. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of OraSure Technologies in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, OraSure Technologies currently has a consensus rating of “Reduce” and a consensus price target of $3.00.

OraSure Technologies Price Performance

OSUR opened at $2.96 on Friday. OraSure Technologies, Inc. has a 12 month low of $2.36 and a 12 month high of $4.60. The stock has a market capitalization of $216.49 million, a price-to-earnings ratio of -4.42 and a beta of 0.46. The business has a fifty day moving average price of $3.15 and a 200 day moving average price of $3.01.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.